Ohsong Pharm, a pharmaceutical company specializing in targeted products for the Japanese market, announced today that it has been selected for the **Strong+ stage**, the highest level of the **"1000+ Global Strong Companies"** program organized by the Ministry of SMEs and Startups.
The **1000+ Global Strong Companies** program selects export SMEs with high growth potential and supports their development into leading export companies by offering preferential assistance in areas such as marketing, finance, and more.
By founding Brio Pharma in Japan, Ohsong Pharm has effectively overcome the barriers typically faced by foreign pharmaceutical companies entering the Japanese market. In February, the company received approval for escitalopram tablets, an SSRI antidepressant developed in collaboration with Whan In Pharm. Then, on June 1, it earned Class 2 Medical Device Manufacturing and Marketing Licenses, solidifying its role as a leading pharmaceutical exporter to Japan.
A representative of Ohsong Pharm stated, “Being selected for the Global 1000+ Global Strong Companies program showcases Ohsong Pharm's exceptional export performance, expertise, and growth potential. We will continue to expand our business to include not only pharmaceuticals but also medical devices and pharmaceutical raw materials. With our diverse experience and know-how, we aim to be the best business partner for both domestic and foreign pharmaceutical companies looking to enter the Japanese market.”